4dmt announces positive phase 2 prism interim results for intravitreal 4d-150 in a broad wet amd population affirming favorable safety profile and robust clinical activity

Emeryville, calif., july 17, 2024 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive initial interim 24-week landmark data from the population extension cohort of the prism phase 2 clinical trial, which evaluated intravitreal 4d-150 in a broad wet amd patient population. the data were presented by raj k. maturi, m.d., in an oral presentation titled, “phase 2 population extension cohort in the prism trial evaluating 4d-150 in adults with neovascular age-related macular degeneration,” at the american society of retina specialists (asrs) annual scientific meeting held in stockholm, sweden.
AMD Ratings Summary
AMD Quant Ranking